
---
title: '上海医药：B013注射剂获得II_III期临床试验批准通知书'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=2384'
author: 证券时报网
comments: false
date: Mon, 22 Aug 2022 17:04:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=2384'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS601607" style="color: #2f67d1;text-decoration: none;" code="601607" target="_blank">上海医药</a>(601607)8月22日晚间公告，全资子公司上海交联药物的B013注射剂获得II/III期临床试验批准通知书。产品拟用适应症为一线治疗局部晚期或转移性三阴性乳腺癌。</p>

                  
</div>
            